• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在乳腺高级别导管原位癌中,∆Np63(使用p40抗体)的免疫染色与p63和CK5/6的免疫染色相同。

Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.

作者信息

Sailer Verena, Lüders Christine, Kuhn Walther, Pelzer Volker, Kristiansen Glen

机构信息

Institute of Pathology, University of Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany,

出版信息

Virchows Arch. 2015 Jul;467(1):67-70. doi: 10.1007/s00428-015-1766-z. Epub 2015 Apr 8.

DOI:10.1007/s00428-015-1766-z
PMID:25850754
Abstract

As a result of breast cancer screening programs, high-grade ductal carcinoma in situ (DCIS) of the breast is diagnosed more often. Frequently, a DCIS diagnosis can only be made using immunohistochemical stains to visualize the myoepithelial layer in order to assess microinvasion. Standard markers for myoepithelial cells are CK5/6 and p63. An isoform of the latter, ∆Np63, is recognized by a recently developed antibody, p40. Here, we compare the standard myoepithelial markers CK5/6 and p63 with p40. We immunostained full sections of tissue samples of 35 high-grade DCIS and compared the staining pattern of CK5/6, p63 and p40 in tumour tissue and in normal glands. Staining patterns of myoepithelial cells for p63 and p40 were similar in terms of the percentage of stained nuclei. In all cases, p63 was strongly expressed, while this was the case for p40 in 31 (89%) and moderately in 4 (11%) cases. All but one case (97%) showed a similar percentage of stained myoepithelial cells in comparing CK5/6 and p40 staining. CK5/6 expression was heterogeneous and strong/moderate/weak in 60, 34 and 6 % respectively. Compared to surrounding normal glands, staining of myoepithelial cells for all three markers in the neoplastic lesion was attenuated. In high-grade DCIS, p40 staining is highly specific for myoepithelial cells. Its staining pattern and intensity are equal to p63, which opens up its use for daily practice. Staining with p40 is less heterogeneous than that for CK5/6.

摘要

由于乳腺癌筛查项目,乳腺高级别导管原位癌(DCIS)的诊断更为常见。通常,DCIS的诊断只能通过免疫组化染色来观察肌上皮层,以评估微浸润情况。肌上皮细胞的标准标志物是CK5/6和p63。后者的一种异构体∆Np63可被一种新开发的抗体p40识别。在此,我们将标准的肌上皮标志物CK5/6和p63与p40进行比较。我们对35例高级别DCIS组织样本的全切片进行免疫染色,并比较了肿瘤组织和正常腺体中CK5/6、p63和p40的染色模式。就染色细胞核的百分比而言,p63和p40的肌上皮细胞染色模式相似。在所有病例中,p63均强烈表达,而p40在31例(89%)中强烈表达,4例(11%)中中度表达。除1例(97%)外,在比较CK5/6和p40染色时,所有病例的肌上皮细胞染色百分比相似。CK5/6的表达具有异质性,分别在60%、34%和6%的病例中呈强/中/弱表达。与周围正常腺体相比,肿瘤病变中所有三种标志物的肌上皮细胞染色均减弱。在高级别DCIS中,p40染色对肌上皮细胞具有高度特异性。其染色模式和强度与p63相当,这使其可用于日常实践。p40染色的异质性低于CK5/6染色。

相似文献

1
Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.在乳腺高级别导管原位癌中,∆Np63(使用p40抗体)的免疫染色与p63和CK5/6的免疫染色相同。
Virchows Arch. 2015 Jul;467(1):67-70. doi: 10.1007/s00428-015-1766-z. Epub 2015 Apr 8.
2
Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.导管原位癌相关肌上皮细胞的表型和功能特征
Clin Breast Cancer. 2015 Oct;15(5):335-42. doi: 10.1016/j.clbc.2015.01.004. Epub 2015 Jan 21.
3
p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.乳腺细针穿刺抽吸物中肌上皮细胞的p63染色:关于其在乳腺原位导管癌与浸润性导管癌鉴别中作用的研究
J Clin Pathol. 2002 Dec;55(12):936-9. doi: 10.1136/jcp.55.12.936.
4
Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.导管原位癌的基底样表型:识别与免疫组织学特征
Mod Pathol. 2006 Nov;19(11):1506-11. doi: 10.1038/modpathol.3800678. Epub 2006 Aug 25.
5
The significance of combined CK5/6 and p63 immunohistochemistry in predicting the risks of subsequent carcinoma development in intraductal papilloma of the breast.联合CK5/6和p63免疫组化在预测乳腺导管内乳头状瘤后续发生癌变风险中的意义。
Pathol Int. 2015 Feb;65(2):81-8. doi: 10.1111/pin.12248. Epub 2015 Jan 8.
6
The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.P63/细胞角蛋白7/18/细胞角蛋白5/14抗体组合在乳腺病理诊断中的临床应用
Ann Diagn Pathol. 2014 Dec;18(6):313-8. doi: 10.1016/j.anndiagpath.2014.08.007. Epub 2014 Aug 27.
7
P40 Immunostain Does Not Outperform p63 as a Myoepithelial Cell Marker in the Daily Practice of Breast Pathology.在乳腺病理学日常实践中,P40免疫染色作为肌上皮细胞标志物并不优于p63。
Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):599-604. doi: 10.1097/PAI.0000000000000507.
8
Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.CK5/6、ER、p63 和 MUC3 联合评估在鉴别乳腺导管内乳头状瘤与导管原位癌中的作用。
Pathol Int. 2012 Jun;62(6):381-90. doi: 10.1111/j.1440-1827.2012.02811.x. Epub 2012 Mar 30.
9
Head-to-Head Comparison of p63 and p40 in Non-Neuroendocrine Carcinomas of the Tubal Gut.输卵管肠道非神经内分泌癌中p63和p40的直接比较
Int J Surg Pathol. 2020 Dec;28(8):835-843. doi: 10.1177/1066896920924821. Epub 2020 May 28.
10
Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells.乳腺导管原位癌中与间质浸润相关的形态学、分子和微环境因素:肌上皮细胞的作用
Breast Dis. 2015;35(4):249-52. doi: 10.3233/BD-150416.

引用本文的文献

1
Dimorphic cells: a common feature throughout the low nuclear grade breast neoplasia spectrum.两态细胞:低核级乳腺肿瘤谱中普遍存在的共同特征。
Virchows Arch. 2023 Feb;482(2):369-375. doi: 10.1007/s00428-022-03438-w. Epub 2022 Nov 15.
2
p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.三阴性乳腺癌中的p63亚型:ΔNp63与基底样表型相关,而TAp63与雄激素受体、无BRCA突变、PTEN以及生存期改善相关。
Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.
3

本文引用的文献

1
Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.根据 HER2 扩增状态和分子亚型对乳腺导管原位癌 (DCIS) 的组织病理学特征进行描述。
Virchows Arch. 2014 Sep;465(3):275-89. doi: 10.1007/s00428-014-1609-3. Epub 2014 Jun 29.
2
p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry.p40(ΔNp63)在乳腺疾病中的表达及其与p63免疫组化的相关性。
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1032-41. eCollection 2014.
3
Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis.
乳腺钼靶检查显示致密的人类乳腺组织会促使MCF10DCIS.com进展为浸润性病变并发生转移。
Breast Cancer Res. 2016 Oct 25;18(1):106. doi: 10.1186/s13058-016-0767-4.
4
Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells.乳腺上皮细胞中突变型Ras对p63的抑制作用及上皮-间质转化的诱导
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6107-E6116. doi: 10.1073/pnas.1613417113. Epub 2016 Sep 28.
导管原位癌的治疗:利弊平衡尚不确定。
Prescrire Int. 2013 Dec;22(144):298-303.
4
DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.DEGRO 实践指南:乳腺癌放疗 II:乳腺非浸润性肿瘤放疗。
Strahlenther Onkol. 2014 Jan;190(1):8-16. doi: 10.1007/s00066-013-0502-3.
5
Progression from ductal carcinoma in situ to invasive breast cancer: revisited.从导管原位癌到浸润性乳腺癌的进展:再探讨。
Mol Oncol. 2013 Oct;7(5):859-69. doi: 10.1016/j.molonc.2013.07.005. Epub 2013 Jul 12.
6
Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells?比较前列腺组织中 p40(ΔNp63)和 p63 的表达--哪一个是基底细胞的更佳诊断标志物?
Histopathology. 2013 Jul;63(1):50-6. doi: 10.1111/his.12116. Epub 2013 May 13.
7
Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.乳腺导管癌原位及浸润性成分的核分级和免疫组化特征比较
Rev Bras Ginecol Obstet. 2013 Mar;35(3):97-102. doi: 10.1590/s0100-72032013000300002.
8
Use of immunohistochemistry in the diagnosis of problematic breast lesions.应用免疫组织化学技术诊断有问题的乳腺病变。
J Clin Pathol. 2013 Jun;66(6):471-7. doi: 10.1136/jclinpath-2012-201109. Epub 2013 Mar 13.
9
Is DCIS breast cancer, and how do I treat it?DCIS 是乳腺癌吗?我应该如何治疗?
Curr Treat Options Oncol. 2013 Mar;14(1):75-87. doi: 10.1007/s11864-012-0217-1.
10
The benefits and harms of breast cancer screening: an independent review.乳腺癌筛查的获益与危害:一项独立评审。
Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0. Epub 2012 Oct 30.